🇨🇿 Medical cannabis in Czechia

B — controlled national programme. Pharmacy-prepared cannabis is prescribed only by doctors in listed specialties, on an e-prescription flagged as a highly addictive substance, within a 180 g monthly cap; public insurance pays 90 % of up to 30 g a month.

SÚKL (Státní ústav pro kontrolu léčiv, State Institute for Drug Control) page for professionals (updated 5 May 2025): prescribing under vyhláška č. 236/2015 Sb. is limited to specialists in clinical/radiation oncology, neurology, palliative medicine, pain management, rheumatology, orthopaedics, infectious diseases, internal medicine, ophthalmology, dermatology, geriatrics and psychiatry — general practitioners are not on the list; permitted material has THC up to 25 % and CBD up to 23 %; the cap is '180 g usušené rostlinné drogy měsíčně' (1 g extract = 3 g plant); the prescription must be electronic and marked 'vysoce návyková látka', with product code 9190000 (cannabis) or 9390000 (extract) and THC/CBD content; a single prescription may cover at most 3 months; hospital orders use the žádanka s modrým pruhem. Reimbursement: '90 % ceny pro konečného spotřebitele, v množství nejvýše 30 g konopí' per month in outpatient care, more with insurer approval. Licensing of cultivation sits with the state cannabis agency inside SÚKL.

Source: SÚKL — Konopí pro léčebné použití: druhy, indikace a specializace lékařů (medical cannabis: types, indications, prescriber specialties), updated 5 May 2025 · read 27 September 2026

Only pharmacy-made magistral preparations (IPLP) from dried Cannabis sativa flower or a cannabis extract — there is no branded medical-cannabis product to ask for. The doctor writes a percentage of THC and CBD, not a strain name.

Vyhláška č. 236/2015 Sb., § 2 odst. 1: cannabis of the species Cannabis sativa or an extract, for which 1 g of extract counts as 3 g of dried herb. § 5 odst. 2 caps potency: THC max 25.0 %, CBD max 23.0 %. Since 1 April 2025 all older product codes are abolished and only two prescribing codes exist — 9190000 (konopí pro léčebné použití, dried) and 9390000 (extrakt z konopí pro léčebné použití) — with the requested THC/CBD percentages written into the eRecept. The pharmacist may substitute within a ±10 % tolerance (§ 5 odst. 3). Cannabis flower now has its own European Pharmacopoeia monograph (Cannabis flos 3028, Český lékopis 2023, Doplněk 2024), which no longer distinguishes indica from sativa. Separately, two finished cannabis-derived medicines are registered in the SÚKL drug database: EPIDYOLEX (cannabidiol, N03AX24, EU/1/19/1389) and SATIVEX (nabiximols, N02BG10, reg. 63/256/11-C) — but in the 27 August 2026 DLP open data every SATIVEX pack has DODAVKY=0, i.e. not supplied to Czech pharmacies in the last six months.

Source: Vyhláška č. 236/2015 Sb., § 2 a § 5, ve znění vyhlášky č. 12/2025 Sb. (zakonyprolidi.cz) · read 6 September 2026

A doctor holding one of the specialisations listed in příloha č. 3 to vyhláška č. 236/2015 Sb., who has also been granted access to the RLPO register. Since 1 April 2025 this includes general practitioners — but only for the single indication of chronic intractable pain.

Vyhláška č. 12/2025 Sb. (issued 8 January 2025, published 16 January 2025, effective 1 April 2025) added "všeobecné lékařství" to příloha č. 3, and only under the heading "chronická neutišitelná bolest". The other permitted specialisations, unchanged, are: klinická onkologie, radiační onkologie, neurologie, paliativní medicína, léčba bolesti, revmatologie, ortopedie, infekční lékařství, vnitřní lékařství, oftalmologie, dermatovenerologie, geriatrie and psychiatrie — each tied to specific indications, so a psychiatrist may prescribe only for Gilles de la Tourette syndrome and a dermatovenerologist only for skin and mucosal lesions, nausea/appetite, or pain. The same vyhláška opened prescribing for under-18s, but only by a doctor with zvláštní specializovaná způsobilost in palliative medicine or working in a centre of highly specialised paediatric haemato-oncological or oncological care (§ 4 odst. 1 písm. b)). Beyond the specialisation, the doctor must apply for prescribing access at https://pristupy.sukl.cz; the previous duty to file electronic treatment-outcome reports was abolished. Pharmacists get RLPO access automatically. On the numbers: SÚKL's own published statistics count doctors who actually issued a prescription in a given month — 197 to 228 per month through 2024, 236 in March 2025 (immediately before the reform), 305 in December 2025 and 345 in June 2026. The widely repeated figure of 806 prescribers comes from a Czech Television report of 26 February 2026 (257 GPs, 226 neurologists, 110 pain specialists, 107 palliative-care doctors, remainder unspecified) and is attributed to no named source; it is a count of doctors permitted to prescribe, not of doctors who do.

Source: Vyhláška č. 12/2025 Sb. (Sagit, plné znění) + SÚKL, Statistika výdejů konopí pro léčebné použití v lékárnách, list "ostatni", KLP_2025-12.xlsx a KLP_2026-06.xlsx · read 6 September 2026

An electronic prescription flagged "vysoce návyková látka" (the restricted eRecept). Every issue and every dispensing is checked against the Registr pro léčivé přípravky s omezením (RLPO), which enforces the quantity ceiling in real time.

Vyhláška č. 236/2015 Sb., § 4 odst. 2 requires the eRecept to carry the "vysoce návyková látka" flag plus dosing, route of administration, code 9190000 or 9390000, and the requested THC/CBD percentages. § 4 odst. 3 (as amended from 1 April 2025): "Připravovaný léčivý přípravek s obsahem konopí pro léčebné použití podle § 2 lze předepsat na jeden recept nejvýše v množství odpovídajícím dávce pro zajištění tříměsíční léčby pro danou indikaci" — one prescription may now cover three months of treatment, up from one. The statutory ceiling in § 2 odst. 1 stays "v souhrnném množství nejvýše 180 g usušené rostlinné drogy měsíčně", so in practice the rolling window is 540 g per 90 days in total and 90 g per 90 days at the reimbursed rate. Before preparing anything the pharmacist queries the RLPO to see how many grams the patient may still receive in the current window. In inpatient care a paper žádanka s modrým pruhem is used instead, capped at 6 g dried herb or 2 g extract per day (§ 2 odst. 2). The restricted eRecept is valid 14 calendar days, extendable to a maximum of 30, under vyhláška č. 329/2019 Sb.

Source: Vyhláška č. 236/2015 Sb., § 2 a § 4, ve znění vyhlášky č. 12/2025 Sb.; ePreskripce (NZIS/MZ ČR), "Jak je možné vydat konopí pro léčebné použití po 1. 4. 2025", 15. 4. 2025 · read 6 September 2026

Lawful in principle, and used in practice. Czech law recognises telemedicine (§ 11c zákona č. 372/2011 Sb.) and contains no rule requiring an in-person examination before a cannabis prescription, and no cannabis- or narcotic-specific exception. The practical gate is not distance but the doctor's RLPO access.

§ 11c zákona č. 372/2011 Sb., o zdravotních službách, inserted by the autumn 2024 amendment (zákon č. 240/2024 Sb.), defines telemedicínské zdravotní služby as "zdravotní služby, které jsou poskytovány na dálku za použití informačních a telekomunikačních technologií nebo zdravotnického prostředku", conditional only on encrypted communication, technical quality and security requirements, and proof of identity of both parties; recording requires the patient's consent. Nothing in § 11c, in vyhláška č. 236/2015 Sb. or in vyhláška č. 329/2019 Sb. bars remote issue of a restricted eRecept or requires prior physical examination. The doctor's ordinary professional duty (postup lege artis) still applies, and the Society of General Practitioners' 2026 telemedicine guideline warns explicitly against prescribing on request without proper review. Commercial Czech services do prescribe cannabis largely online — Konopná klinika states "Většinu konzultací nabízíme online, aby léčba byla dostupná i pacientům s omezenou pohyblivostí" — but they are ordinary healthcare providers, not a separately regulated category.

Source: Zákon č. 372/2011 Sb., o zdravotních službách, § 11c (zakonyprolidi.cz) · read 6 September 2026

Any Czech pharmacy may legally prepare and dispense it — no licence, no contract and no notification to SÚKL is required. In practice only a minority actually do, and there is no official list, so a patient has to ring around or ask the prescribing doctor.

Česká lékárnická komora, Doporučený postup "Konopí pro léčebné použití", verze 2.0 ze dne 22. 4. 2026: "Lékárna nepotřebuje žádné speciální povolení (licenci) nebo smlouvu k zacházení s konopím pro léčebné použití. Jedná se o přípravu léčivých přípravků, která nepodléhá ohlašovací povinnosti SÚKL." Handling of the narcotic is permitted directly by zákon č. 167/1998 Sb. Because there is no authorisation step, no authority holds a list of which pharmacies do it. SÚKL's official pharmacy register (Seznam lékáren, open data, 2,689 entries at 27 August 2026) records name, address, ICZ/IČO, responsible pharmacist, opening hours, e-prescription flag, mail-order flag and pharmacy type — and nothing at all about cannabis. Before starting a preparation the pharmacist must check the RLPO for the patient's remaining allowance; recommended practice is to dispense the insurance-covered portion first and any reviewing-doctor-approved excess afterwards.

Source: Česká lékárnická komora, Doporučený postup: Konopí pro léčebné použití, verze 2.0, 22. 4. 2026, kap. 4 · read 6 September 2026

Public health insurance pays 90% of the final consumer price for up to 30 g of cannabis per month in outpatient care. Above 30 g the insurer must approve in advance, and can approve up to the statutory ceiling of 180 g a month.

The provision is § 32b zákona č. 48/1997 Sb., o veřejném zdravotním pojištění (not § 15): "(1) Ze zdravotního pojištění se při poskytování ambulantní zdravotní péče hradí individuálně připravovaný léčivý přípravek s obsahem konopí pro léčebné použití předepsaný podle jiného právního předpisu, a to ve výši 90 % ceny pro konečného spotřebitele, v množství nejvýše 30 g konopí pro léčebné použití měsíčně." § 32b odst. 3 lets the insurer approve more "vyžaduje-li to zdravotní stav pojištěnce, nejvýše však v množství odpovídajícím limitu stanovenému jiným právním předpisem" — i.e. up to 180 g/month; § 19 odst. 1 písm. j) makes that prior approval mandatory. Because 1 g of extract counts as 3 g of herb, the reimbursed extract quantity is 10 g per month. Under the three-month prescription introduced in April 2025 this is administered as 90 g reimbursed / 540 g total per 90 days. There is no separate indication restriction on reimbursement: the 90% applies to every indication in příloha č. 3, in outpatient care only — inpatient use is not reimbursed under § 32b. The 10 % co-payment does not count towards the annual ochranný limit for most patients: § 16b odst. 1 zákona č. 48/1997 Sb. expressly excludes co-payments on partially reimbursed individually prepared medicines — "to neplatí" only for insured persons over 65, for whom the limit (1 000 Kč, or 500 Kč from 70) does absorb them.

Source: Zákon č. 48/1997 Sb., § 32b a § 19 odst. 1 písm. j) (zakonyprolidi.cz) · read 6 September 2026

The patient pays 10% of the final price of the preparation. The state caps the supply price at 141.88 Kč per gram of cannabis and 425.64 Kč per gram of extract, both excluding VAT — but no official source publishes a typical final price, because each preparation is priced individually.

Cenový výměr Ministerstva zdravotnictví č. 2/2025/OLZP, effective 1 September 2025, Article II: "Maximální cena za 1 gram konopí pro léčebné použití, která může být uplatněna při dodávkách připravující lékárně, činí 141,88 Kč" and for extract "425,64 Kč" (= 3 × 141.88, mirroring the 1 g extract : 3 g herb conversion). The final consumer price is built up per preparation from the acquisition cost of the cannabis actually used (no trade markup permitted on the cannabis itself), excipients, containers and labels at a markup of at most 10 %, taxa laborum, and — for capsules — a decarboxylation charge of at most 160.95 Kč per technological cycle. Price regulation applies whether or not the preparation is reimbursed, so it also caps what a self-paying patient can be charged. Derived illustration, not an official figure: at the ceiling price the cannabis component alone of a 30 g month is 4,256.40 Kč excluding VAT, so the 10 % co-payment is on the order of 430–500 Kč a month before VAT, taxa laborum and excipients. Cannabis for medical use is not subject to any consumption tax, and Sativex and Epidyolex are priced under the ordinary reimbursement system, separately from this decree.

Source: Cenový výměr MZ ČR č. 2/2025/OLZP o regulaci cen individuálně připravovaných LP s obsahem konopí pro léčebné použití, účinný od 1. 9. 2025 · read 6 September 2026

Czechia has a numeric THC limit — 2 ng/ml in blood serum — and there is no medical exemption. A prescription does not make you legal; it only helps you argue at the roadside. Treat 12 hours since the last dose as the minimum safe gap.

§ 5 odst. 2 písm. b) zákona č. 361/2000 Sb.: a driver must not drive "bezprostředně po požití alkoholického nápoje nebo užití jiné návykové látky nebo v takové době ..., kdy by mohl být ještě pod vlivem"; and "v případě jiných návykových látek uvedených v prováděcím právním předpise se řidič považuje za ovlivněného takovou návykovou látkou, pokud její množství v krevním vzorku řidiče dosáhne alespoň limitní hodnoty stanovené prováděcím právním předpisem." The implementing regulation is nařízení vlády č. 41/2014 Sb., which sets delta-9-THC at 2 ng/ml; § 1 odst. 2 specifies that the sample is blood serum. The word "léčivo" does not appear anywhere in zákon č. 361/2000 Sb., and neither the act nor the nařízení contains any exception for medically prescribed use. At or above 2 ng/ml the driver is treated as influenced (an offence); The line to the criminal offence — § 274 trestního zákoníku, "stav vylučující způsobilost" — has no number in the statute; it comes from Supreme Court case-law. In its Criminal College opinion of 21 October 2020 (Tpjn 300/2020, č. 2/2020 Sb. rozh. tr.) the Nejvyšší soud held that a driver with at least 10 ng/ml delta-9-THC in blood serum is deemed to be in that state, so a toxicology report alone can carry a conviction; below it prosecution is still possible but needs a psychiatric expert to prove actual impairment. The figure originated in a 2014 Bohnice expert opinion, was first applied in 7 Tdo 979/2015 and adopted for prosecutors in the Supreme Public Prosecutor's instruction No. 5/2019. Both figures — 2 ng/ml and 10 ng/ml — are serum values, so they are directly comparable. § 5 odst. 2 písm. c) separately forbids driving whenever the medical condition itself impairs fitness. The Czech Chamber of Pharmacists advises patients to avoid driving for at least 6–8 hours and preferably 12 hours after a dose, says a blanket driving ban on patients is not justified if dosing guidance is followed, and advises carrying a medical report or card documenting the treatment, insisting on a blood test rather than accepting a roadside screening result — "běžné orientační testy budou samozřejmě pozitivní".

Source: Zákon č. 361/2000 Sb., § 5 odst. 2 písm. b) a c); nařízení vlády č. 41/2014 Sb., § 1 a příloha (Sagit) · read 6 September 2026

There is no Czech Schengen Article 75 certificate for medical cannabis. No Czech authority — Ministry of Health, SÚKL or Customs — publishes a form or a procedure, and the personal-use export exemption in the narcotics act does not cover pharmacy-made preparations. Assume you cannot lawfully take it out of the country.

§ 20 odst. 1 zákona č. 167/1998 Sb. requires a Ministry of Health export permit (vývozní povolení) for every single export of a narcotic substance or preparation. The personal-travel exemption in § 20 odst. 2 písm. a) applies only "k vývozu hromadně vyráběných léčivých přípravků obsahujících návykové látky ... pokud jsou vyváženy ... fyzickou osobou pro vlastní potřebu v množství a druhu odpovídajícím délce cesty a zdravotnímu stavu podle stanovené diagnózy" — mass-produced medicinal products. A Czech cannabis IPLP is by definition individually prepared, not hromadně vyráběný, so the exemption does not reach it; § 21 odst. 2 písm. a) mirrors this on import. Cannabis for medical use is a narcotic in seznam č. 1 (příloha č. 1) of nařízení vlády č. 463/2013 Sb. The Ministry of Health's narcotics-and-precursors section (checked 2026-09-06) lists no travel certificate; neither the Customs Administration's page for private individuals nor the Ministry of Foreign Affairs' "Cestování s léky" page (19. 6. 2025) mentions Article 75 of the Schengen Convention or any issuing authority. The Czech Chamber of Pharmacists states plainly: "Pro cesty do zahraničí a vývoz IPLP s obsahem léčebného konopí za hranice státu neexistuje jednoznačné doporučení. Je na straně pacienta, aby si zjistil, jaké jsou podmínky a požadavky cílové destinace." Registered finished products (Epidyolex, and Sativex where supplied) are mass-produced and would fall under the exemption.

Source: Zákon č. 167/1998 Sb., o návykových látkách, § 20 a § 21 (úplné znění MZ ČR ke dni 1. 1. 2026); ČLnK Doporučený postup KLP v2.0, 22. 4. 2026 · read 6 September 2026

Only a Czech specialist can prescribe, and the prescription must be a Czech e-prescription marked as a highly addictive substance, so a prescription from another country cannot be filled here and a visitor would need to be treated by a listed Czech specialist. Travel with your own medicine needs a Schengen Article 75 certificate (up to 30 days); Czech rules for non-Schengen visitors were not found on official pages.

1. Non-residents: SÚKL sets no nationality or residency condition, but the prescription must be an eRecept with the 'vysoce návyková látka' flag issued by a doctor of the listed specialties; how a patient without a Czech birth number/insurance number is identified in eRecept is on the epreskripce.gov.cz FAQ, which could not be rendered ('not published' here). 2. Prescriptions from another EU state: Directive 2011/24/EU Art. 11(1) recognition applies in Czechia through zákon č. 378/2007 Sb. (Medicines Act) § 80, but Art. 11(6) permits excluding 'medicinal products subject to special medical prescription'; Czech cannabis prescriptions are in that category (electronic prescription marked as highly addictive substance; blue-stripe forms in hospitals), so foreign cannabis prescriptions are not dispensable in practice — the § 80 text could not be opened (e-Sbírka JavaScript), so the exact exclusion wording is not verified. Cross-border eRecept (epreskripce.gov.cz) currently exchanges e-prescriptions with Estonia, Finland, Cyprus, Latvia, Lithuania, Poland, Austria, Greece, Spain (both directions), Croatia and Portugal (one direction) — the exclusion list for that service was not visible. 3. Bringing medicine in: Schengen Convention Art. 75 certificate for up to 30 days applies to Schengen residents entering Czechia; the Ministry of Health form list (vyhláška 53/2014 Sb. forms) contains no traveller certificate and no MZ page on personal import was found, so the Czech issuing authority and non-Schengen/quantity rules are 'not published' on the pages opened. 4. Foreign telemedicine prescriptions: not dispensable (see 2).

Source: Directive 2011/24/EU on patients' rights in cross-border healthcare, Article 11 (EUR-Lex) · read 27 September 2026

No pending change to the medical-cannabis programme was found on the SÚKL or Ministry of Health pages opened. The 2025 'psychomodulatory substances' framework (kratom etc.) sits beside, not inside, the medical cannabis rules. A reported extension of prescribing to GPs is not reflected on SÚKL's May 2025 prescriber list.

Ministry of Health (Ministerstvo zdravotnictví ČR) news: Nařízení vlády č. 456/2025 Sb. (government regulation listing psychomodulační látky) was promulgated 11 Nov 2025 and took effect 12 Nov 2025, with forms under vyhláška č. 147/2025 Sb. — this concerns kratom-type substances, not medicinal cannabis. The MZ legislation list also cites Nařízení vlády č. 419/2024 Sb. amending the schedules of návykové látky. SÚKL's professional page (5 May 2025) still limits prescribing to the listed specialties, so the 'GP extension' anchor could not be confirmed; the SÚKL public cannabis page carries no news item. Whether the 2026 e-Sbírka consolidation of zákon č. 167/1998 Sb. (Addictive Substances Act) changed the cannabis chapters could not be checked (e-Sbírka is JavaScript-only for this tool).

Source: Ministerstvo zdravotnictví ČR (Ministry of Health) — Návykové látky a prekursory drog: news and legislation list · read 27 September 2026

SÚKL publishes real numbers, monthly and openly: 389,997 g (390.0 kg) of cannabis was dispensed in Czech pharmacies in 2025, up 48.2% on 2024, and between 3,463 and 4,519 individual patients received it in any given month. There is no published count of unique patients over a whole year.

SÚKL, "Statistika výdejů konopí pro léčebné použití v lékárnách" (published 30. 1. 2016, last updated 2. 7. 2026), spreadsheets KLP_2025-12.xlsx and KLP_2026-06.xlsx, sheet "vydej" and sheet "ostatni". Dispensed (vydáno): 263,104.53 g in 2024 → 389,997.24 g in 2025, +48.2%; 256,410.94 g in the first six months of 2026. Prescribed (předepsáno) is a separate, higher series: 318,710.22 g in 2024 → 440,604.16 g in 2025, +38.2%. Prescriptions in 2025: 54,748. Monthly unique patients ("Pacientů") in 2025 ranged 3,463 (August) to 4,286 (April), and reached 4,519 in June 2026. Important caveat: the annual "Total" rows in these files are arithmetic sums of the monthly figures — 45,985 patients and 3,221 doctors for 2025 — so they double-count anyone appearing in more than one month and are NOT annual unique headcounts. Media reports of "46,000 Czech medical cannabis patients" derive from that Total row and overstate the true annual population by roughly an order of magnitude. SÚKL publishes no annual unique patient figure.

Source: SÚKL, Statistika výdejů konopí pro léčebné použití v lékárnách (KLP_2025-12.xlsx, KLP_2026-06.xlsx, KLP_2024.pdf), aktualizováno 2. 7. 2026 · read 6 September 2026